Related Experiment Video

Updated: May 10, 2026

Next Generation Sequencing for the Detection of Actionable Mutations in Solid and Liquid Tumors
11:15

Next Generation Sequencing for the Detection of Actionable Mutations in Solid and Liquid Tumors

Published on: September 20, 2016

Comprehensive Genomic Profiling Across Diverse Solid Tumors: A Real-World Experience From India With

Pramod K Julka1, Deepika Arya1, Sanjay Gupta2

  • 1Medical Oncology, Max Super Speciality Hospital, Saket, Delhi, IND.

Cureus
|February 20, 2026
PubMed

Insights

FoundationOne®CDx (F1CDx) comprehensive genomic profiling identified diverse actionable genomic alterations in Indian patients with various solid tumors. This approach shows significant potential for advancing precision oncology and expanding targeted therapy options in real-world practice.

Area of Science:

  • Oncology
  • Genomics
  • Molecular Diagnostics

Background:

  • Precision oncology increasingly utilizes comprehensive genomic profiling (CGP) via next-generation sequencing (NGS) assays like FoundationOne®CDx (F1CDx) to guide targeted therapies.
  • Understanding the mutational landscape and actionable alterations in diverse solid tumors is crucial for optimizing treatment strategies.

Purpose of the Study:

  • To evaluate the mutational landscape, identify actionable genomic alterations, and assess the clinical utility of F1CDx testing in a diverse cohort of solid tumors at an Indian oncology center.
  • To analyze the frequency and types of genomic alterations across common and rare cancer types in the Indian population.

Main Methods:

  • A retrospective analysis of de-identified demographic, clinical, and genomic data from 115 adult patients who underwent F1CDx testing between August 2017 and April 2025.
  • Somatic alterations were prioritized, and gene-level alteration frequencies were calculated. Descriptive statistics summarized clinical and molecular findings. Genomic actionability was assessed based on report-level or biological relevance.

Main Results:

  • The most common cancers included breast (n=35), gastrointestinal (n=22), lung (n=18), and gynecologic (n=15).
  • Distinct tissue-specific genomic signatures were observed, involving MAPK, PI3K/AKT/mTOR, RTK, DNA repair, and cell cycle pathways.
  • F1CDx identified actionable alterations recommending FDA-approved therapies in 41.7% of cases and tumor-agnostic or off-label therapies in 50.4%.

Conclusions:

  • F1CDx comprehensive genomic profiling revealed a wide array of actionable alterations across various solid tumors in the Indian context.
  • The study highlights the potential of F1CDx to broaden therapeutic options and enhance the practice of precision oncology in real-world Indian clinical settings.
  • Genomic signatures varied by tumor type, underscoring the need for tailored diagnostic approaches.
Keywords:
foundationone®cdxgenomic profilingngs testingprecision oncologysomatic mutations

More Related Videos

Integration of Wet and Dry Bench Processes Optimizes Targeted Next-generation Sequencing of Low-quality and Low-quantity Tumor Biopsies13:24

Integration of Wet and Dry Bench Processes Optimizes Targeted Next-generation Sequencing of Low-quality and Low-quantity Tumor Biopsies

Published on: April 11, 2016

Testing Targeted Therapies in Cancer using Structural DNA Alteration Analysis and Patient-Derived Xenografts10:27

Testing Targeted Therapies in Cancer using Structural DNA Alteration Analysis and Patient-Derived Xenografts

Published on: July 25, 2020

Related Concept Videos

Cancers Originate from Somatic Mutations in a Single Cell02:21

Cancers Originate from Somatic Mutations in a Single Cell

Cancer arises from mutations in the critical genes that allow healthy cells to escape cell cycle regulation and acquire the ability to proliferate indefinitely. Though originating from a single mutation event in one of the originator cells, cancer progresses when the mutant cell lines continue to gain more and more mutations, and finally, become malignant. For example, chronic myelogenous leukemia (CML) develops initially as a non-lethal increase in white blood cells, which progressively...